Arnaud Garnier
CHU Toulouse, Hôpital des Enfants · University Hospital, Toulouse
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arnaud Garnier as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:35 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02956980 · Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells. PLASMACYTOKIDUniversity Hospital, Toulouse · terminated · Innate Immune Responses · principal investigator
- Ph3NCT02205541 · Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHUUniversity Hospital, Toulouse · completed · Hemolytic Uremic Syndrome of Childhood · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:35 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.Bone Marrow Transplant · 201988 citationsRCR 3.5
- Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.J Am Soc Nephrol · 202353 citationsRCR 7.5
- Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.Blood Adv · 202513 citationsRCR 3.6
- 8 citationsRCR 1.8
- 6 citationsRCR 0.9
- Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.Biol Blood Marrow Transplant · 20193 citationsRCR 0.2
- Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.Bone Marrow Transplant · 20172 citationsRCR 0.1
- FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.Cytokine · 20191 citationsRCR 0.0